Avalo Therapeutics Past Earnings Performance
Past criteria checks 0/6
Avalo Therapeutics has been growing earnings at an average annual rate of 7.4%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 1.1% per year.
Key information
7.4%
Earnings growth rate
29.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 1.1% |
| Return on equity | -35.0% |
| Net Margin | -992.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Avalo Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -8 | 15 | 7 |
| 30 Jun 24 | 1 | -19 | 13 | 6 |
| 31 Mar 24 | 1 | -49 | 11 | 5 |
| 31 Dec 23 | 2 | -32 | 10 | 5 |
| 30 Sep 23 | 2 | -33 | 11 | 5 |
| 30 Jun 23 | 17 | -25 | 11 | 6 |
| 31 Mar 23 | 17 | -30 | 12 | 7 |
| 31 Dec 22 | 18 | -42 | 14 | 8 |
| 30 Sep 22 | 17 | -51 | 17 | 10 |
| 30 Jun 22 | 4 | -72 | 20 | 11 |
| 31 Mar 22 | 6 | -76 | 24 | 12 |
| 31 Dec 21 | 5 | -84 | 25 | 11 |
| 30 Sep 21 | 7 | -81 | 24 | 10 |
| 30 Jun 21 | 6 | -77 | 22 | 9 |
| 31 Mar 21 | 4 | -73 | 22 | 8 |
| 31 Dec 20 | 7 | -64 | 20 | 7 |
| 30 Sep 20 | 6 | -54 | 17 | 6 |
| 30 Jun 20 | 7 | -44 | 16 | 3 |
| 31 Mar 20 | 7 | -33 | 12 | 3 |
| 31 Dec 19 | 7 | -16 | 12 | 1 |
| 30 Sep 19 | 0 | -13 | 6 | 1 |
| 30 Jun 19 | 2 | -35 | 8 | 2 |
| 31 Mar 19 | 5 | -38 | 10 | 2 |
| 31 Dec 18 | 7 | -37 | 11 | 2 |
| 30 Sep 18 | 16 | -42 | 17 | 2 |
| 30 Jun 18 | 37 | 2 | 14 | 2 |
| 31 Mar 18 | 32 | 6 | 11 | 2 |
| 31 Dec 17 | 28 | 8 | 9 | 2 |
| 30 Sep 17 | 26 | 13 | 6 | 1 |
| 30 Jun 17 | 1 | -12 | 6 | 2 |
| 31 Mar 17 | 2 | -13 | 6 | 2 |
| 31 Dec 16 | 1 | -16 | 7 | 2 |
| 30 Sep 16 | 1 | -18 | 7 | 2 |
| 30 Jun 16 | 1 | -13 | 6 | 2 |
| 31 Mar 16 | 0 | -12 | 6 | 1 |
| 31 Dec 15 | 0 | -10 | 4 | 2 |
| 30 Sep 15 | 0 | 3 | 4 | 3 |
| 30 Jun 15 | 0 | -2 | 5 | 7 |
| 31 Mar 15 | 0 | -3 | 5 | 11 |
| 31 Dec 14 | 0 | -4 | 5 | 3 |
| 30 Sep 14 | 0 | -17 | 4 | 19 |
Quality Earnings: C6K0 is currently unprofitable.
Growing Profit Margin: C6K0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: C6K0 is unprofitable, but has reduced losses over the past 5 years at a rate of 7.4% per year.
Accelerating Growth: Unable to compare C6K0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: C6K0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: C6K0 has a negative Return on Equity (-35%), as it is currently unprofitable.